Literature DB >> 6342901

Pharmacokinetic drug interactions with propranolol.

A J Wood, J Feely.   

Abstract

Propranolol is widely used in clinical practice and is frequently administered along with other drugs. The co-administration of propranolol and other drugs may result in either propranolol-induced changes in the disposition of other drugs or in effects of the other drugs on the pharmacokinetics of propranolol. These changes may be due to alteration in absorption, metabolism or to haemodynamic effects such as altered liver blood flow. Understanding the pharmacokinetics of propranolol is important to the rational interpretation of the effects of other drugs on propranolol's disposition. The absorption, protein binding and metabolism of propranolol may all be affected by the co-administration of other drugs. Induction of propranolol's metabolism by halofenate, phenytoin, phenobarbitone, rifampicin and alcohol have all been implicated in altering propranolol clearance, while inhibition of hepatic drug metabolising enzymes by chlorpromazine and cimetidine appear to reduce propranolol clearance. Propranolol may also affect the metabolism of other drugs such as antipyrine, chlorpromazine, theophylline and thyroid hormones. Suggestions that propranolol may alter quinidine's elimination have not been substantiated. By reducing liver blood flow propranolol may reduce the systemic clearance of other high extraction drugs such as lignocaine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6342901     DOI: 10.2165/00003088-198308030-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  45 in total

1.  Spuriously low plasma propranolol concentrations resulting from blood collection methods.

Authors:  R H Cotham; D Shand
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

2.  Inhibition of propranolol metabolism by chlorpromazine.

Authors:  R E Vestal; D M Kornhauser; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

3.  Failure of ranitidine to interact with propranolol.

Authors:  A M Heagerty; C M Castleden; L Patel
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-01

4.  The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver.

Authors:  R A Branch; A S Nies; D G Shand
Journal:  Drug Metab Dispos       Date:  1973 Sep-Oct       Impact factor: 3.922

5.  Effect of propranolol on morphine metabolism.

Authors:  S F Brunk; M Delle; W R Wilson
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

6.  Does cimetidine alter the cardiac response to exercise and propranolol?

Authors:  S Warburton; L H Opie; B M Kennelly; F O Müller
Journal:  S Afr Med J       Date:  1979-06-30

7.  The artifactual nature of heparin-induced drug protein-binding alterations.

Authors:  J E Brown; B B Kitchell; T D Bjornsson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

8.  Effects of acute alcohol administration on propranolol absorption.

Authors:  B S Grabowski; W J Cady; W W Young; J F Emery
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-07

9.  Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.

Authors:  K M Kessler; W C Humphries; M Black; J F Spann
Journal:  Am Heart J       Date:  1978-11       Impact factor: 4.749

10.  Impairment of antipyrine clearance in humans by propranolol.

Authors:  D J Greenblatt; K Franke; D H Huffman
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

View more
  16 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.

Authors:  H Y Pan; J Triscari; A R DeVault; S A Smith; D Wang-Iverson; B N Swanson; D A Willard
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

4.  Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon.

Authors:  S Harder; R Brei; S Caspary; P G Merz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.

Authors:  T Kaila; E Iisalo; A Lehtonen; H Saarimaa
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

6.  Dose-dependence of atenolol-ampicillin interaction.

Authors:  A J McLean; A Tonkin; P McCarthy; P Harrison
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

7.  Pharmacokinetic and pharmacodynamic interaction study of diazepam and metoprolol.

Authors:  U Klotz; I W Reimann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Effects of cholestyramine and colestipol on the plasma concentrations of propranolol.

Authors:  D M Hibbard; J R Peters; D B Hunninghake
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

9.  The antinociceptive effect of esmolol.

Authors:  Yoon Hee Kim
Journal:  Korean J Anesthesiol       Date:  2010-09-20

10.  Propranolol does not alter flutoprazepam kinetics and metabolism in the rat.

Authors:  I Conti; S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.